Although intensive insulin therapy delivered by MDI and rapid-acting analogue–based CSII were similarly effective in lowering HbA1c levels with similar rates of hypoglycemia in patients with type 1 diabetes, the finding that rt-CGM was superior to SMBG in lowering HbA1c levels without increasing the risk of severe hypoglycemia in type 1 diabetes patients – particularly those who are compliant with using the device – suggests "the addition of this monitoring method to SMBG and intensive insulin therapy can assist in achieving glycemic targets" in this patient population, the authors wrote.
The authors disclosed no relevant conflicts of interest. The research was supported by the Agency for Healthcare Research and Quality (AHRQ).